Compare · JNJ vs TEVA
JNJ vs TEVA
Side-by-side comparison of Johnson & Johnson (JNJ) and Teva Pharmaceutical Industries Limited (TEVA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JNJ and TEVA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $601.73B, about 16.0x TEVA ($37.52B).
- Over the past year, JNJ is up 53.2% and TEVA is up 97.5% - TEVA leads by 44.4 points.
- JNJ has been more active in the news (10 items in the past 4 weeks vs 5 for TEVA).
- Both have 25 recent analyst ratings on file.
- Company
- Johnson & Johnson
- Teva Pharmaceutical Industries Limited
- Price
- $249.54+1.04%
- $32.23+2.16%
- Market cap
- $601.73B
- $37.52B
- 1M return
- +5.84%
- -4.25%
- 1Y return
- +53.18%
- +97.55%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 10
- 5
- Recent ratings
- 25
- 25
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system and pain area include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. The company was founded in 1901 and is based in Tel Aviv-Yafo, Israel.
Latest JNJ
- Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award
- DePuy Synthes Acquires Expanding Innovations™
- Johnson & Johnson filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026
- Johnson & Johnson reports Q2 2026 results, raises 2026 outlook
- Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform
- Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
- Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis
- SEC Form 11-K filed by Johnson & Johnson
- SEC Form 11-K filed by Johnson & Johnson
Latest TEVA
- Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
- Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
- Teva and Samsung Bioepis Enter Commercialization Agreement for OPUVIZ®, a Biosimilar Referencing Eylea® (aflibercept), in Canada
- Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results
- EVP, Global Operations Shields Matthew sold $321,547 worth of Ordinary Shares (9,989 units at $32.19), closing all direct ownership in the company (SEC Form 4)
- Teva Releases Q2 2026 Aide Memoire
- Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome
- Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ET
- EVP, Chief Financial Officer Kalif Eliyahu Sharon sold $3,633,308 worth of Ordinary Shares (106,563 units at $34.10) as part of a pre-agreed trading plan, decreasing direct ownership by 62% to 65,621 units (SEC Form 4)
- Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy